Recognition of Equity-Method Investment Loss
First written in FY2018-Q3. 14 of 29 entries say "Worsened", first in FY2019-Q1. Latest entry: 2026-08-06.
Stella Chemifa moved to the "Worse" side of this theme in 2023, 2 years after the typical company in this theme (2021).
The whole theme swung hardest in 2023: 19 of 68 companies on the "Worse" side.
31 other companies' latest entry also says "Mitigated".
- 2026-08-06MitigatedEarnings
「持分法による投資損失 73 21」
持分法による投資損失は前年同期の73百万円から21百万円へ減少している。 - FY2026MitigatedAnnual report
「Equity-method investment loss ¥393 million ¥282 million」
The equity-method investment loss decreased from ¥393 million in the previous fiscal year to ¥282 million. - 2026-05-14MitigatedEarnings
「Equity in losses of affiliated companies accounted for using the equity method decreased from ¥153 million in the same period of the previous year to ¥139 million.」
Equity in losses of affiliated companies accounted for using the equity method decreased from ¥393 million in the previous fiscal year to ¥282 million in the current fiscal year. - FY2026-H1MitigatedAnnual report
「Equity-method investment loss 153 139」
Equity in losses of affiliated companies accounted for using the equity method decreased from ¥153 million in the same period of the previous year to ¥139 million. - FY2025WorsenedAnnual report
「Equity-method investment loss ¥393 million」
The equity-method investment loss increased from ¥302 million in the previous fiscal year to ¥393 million. - FY2025-H1WorsenedAnnual report
「Equity-method investment loss 89 153」
The equity-method investment loss increased from ¥89 million in the same period of the previous year to ¥153 million in the current period. - FY2024WorsenedAnnual report
「The company recorded a ¥302 million equity-method investment loss as a non-operating expense.」
The ¥329 million equity-method investment income recorded in the previous fiscal year turned into an investment loss of ¥302 million in the current period. - FY2024-Q3WorsenedAnnual report
「Equity-method investment income 561 — Equity-method investment loss — 148」
Equity-method investment income of ¥561 million in the same period of the previous year changed to an equity-method investment loss of ¥148 million in the current period. - FY2024-Q2WorsenedAnnual report
「Equity-method investment income 489 — Equity-method investment loss — 89」
Equity-method investment income of ¥489 million in the same period of the previous year changed to an equity-method investment loss of ¥89 million in the current period. - FY2024-Q1WorsenedAnnual report
「Equity-method investment income 375 — Equity-method investment loss — 53」
Equity-method investment income of ¥375 million in the same period of the previous year turned into an equity-method investment loss of ¥53 million in the current period. - FY2023WorsenedAnnual report
「In addition, although the company recorded equity-method investment income from its equity-method affiliate, 衢州北斗星化学新材料有限公司, ordinary income was ¥4.347 billion, down 23.8% year on year, following a decline in operating income.」
Although the company recorded equity-method investment income from 衢州北斗星化学新材料有限公司, the amount was ¥329 million in the current consolidated fiscal year, down from ¥994 million in the previous fiscal year. - FY2023-Q3MitigatedAnnual report
「In addition, although the company recorded equity-method investment income due to the solid operating performance of its equity-method affiliate, 衢州北斗星化学新材料有限公司, ordinary income was ¥3.75 billion, down 4.7% year on year, following a decline in operating income.」
Against the backdrop of the solid operating performance of 衢州北斗星化学新材料有限公司, the company recorded equity-method investment income, which increased from ¥382 million in the same period of the previous year to ¥561 million. - FY2023-Q2MitigatedAnnual report
「Equity-method investment income 156 489」
Equity-method investment income increased from ¥156 million in the same period of the previous year to ¥489 million in the current period. The increase in domestic China selling prices for electrolytes used in lithium-ion secondary batteries and the strong operating results at 衢州北斗星化学新材料有限公司 were cited as factors. - FY2023-Q1MitigatedAnnual report
「Equity-method investment income — 375 Equity-method investment loss 26 —」
The equity-method investment loss of ¥26 million in the same period of the previous year changed to equity-method investment income of ¥375 million in the current period. The increase in the selling price of electrolytes and strong operating results at 衢州北斗星化学新材料有限公司 were cited as factors. - FY2022-Q3MitigatedAnnual report
「Equity-method investment income — 382」
The equity-method investment loss of ¥194 million in the same period of the previous year changed to equity-method investment income of ¥382 million in the current period. - FY2022-Q2MitigatedAnnual report
「Equity-method investment income — 156 Equity-method investment loss 142 —」
The equity-method investment loss of ¥142 million in the same period of the previous year changed to equity-method investment income of ¥156 million in the current period. - FY2022-Q1MitigatedAnnual report
「Equity-method investment loss 56 26」
The equity-method investment loss decreased from ¥56 million in the same period of the previous year to ¥26 million in the current period. - FY2021WorsenedAnnual report
「Equity-method investment loss ¥29 million ¥202 million」
The equity-method investment loss increased from ¥29 million in the previous fiscal year to ¥202 million. - FY2021-Q3WorsenedAnnual report
「Equity-method investment loss 34 194」
The equity-method investment loss increased from ¥34 million in the same period of the previous year to ¥194 million in the current period. - FY2021-Q2WorsenedAnnual report
「Equity-method investment income 40 — Equity-method investment loss — 142」
Equity-method investment income of ¥40 million in the same period of the previous year changed to an equity-method investment loss of ¥142 million in the current period. - FY2021-Q1WorsenedAnnual report
「Equity-method investment income 15 — Equity-method investment loss — 56」
Equity-method investment income of ¥15 million in the same period of the previous year changed to an equity-method investment loss of ¥56 million in the current period. - FY2020MitigatedAnnual report
「Equity-method investment loss ¥29 million」
The equity-method investment loss decreased from ¥238 million in the previous year to ¥29 million. - FY2020-Q3MitigatedAnnual report
「Equity-method investment loss 234 34」
The equity-method investment loss decreased from ¥234 million in the same period of the previous year to ¥34 million in the current period. - FY2020-Q2MitigatedAnnual report
「Equity-method investment gains － 40」
Against the ¥191 million equity-method investment loss recorded in the same period of the previous year, the company recorded ¥40 million in equity-method investment income in the current period. - FY2020-Q1MitigatedAnnual report
「Equity-method investment income — 15」
While the company recorded a ¥133 million equity-method investment loss in the same period of the previous year, it recorded ¥15 million in equity-method investment income in the current period. - FY2019-Q3WorsenedAnnual report
「Equity-method investment loss 67 234」
The equity-method investment loss increased from ¥67 million in the same period of the previous year to ¥234 million in the current period. - FY2019-Q2WorsenedAnnual report
「Equity-method investment loss 69 191」
The equity-method investment loss increased from ¥69 million in the same period of the previous year to ¥191 million in the current period. - FY2019-Q1WorsenedAnnual report
「Equity-method investment loss 67 133」
The equity-method investment loss increased from ¥67 million in the same period of the previous year to ¥133 million in the current period. - FY2018-Q3First statedAnnual report
「Equity-method investment loss — 67」
During the first 3 quarters of the current fiscal year, the company recorded a ¥67 million equity-method investment loss as a non-operating expense.